Cencora, Inc.
$339.09-$2.16 (-0.6%)
Last close · Data as of Nov 20, 2026
- Market cap
- $52.6B
- P/E
- 33.8x
- EV / EBITDA
- 14.9x
- Revenue
- $321.3B
- Net margin
- 0.5%
- ROCE
- 21.0%
Price chart
Technical chartScreen technicals →-6.3% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -1.2%
- 3M
- +7.8%
- 6M
- +28.1%
- 1Y
- -6.3%
- 5Y
- +181.4%
52-week range
Day change -$2.16 (-0.6%) from $341 to $339 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in COR, bought on each weekday since 2021.
News & filings
What Cencora filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernNet margin of 0.5% against a peer median of 13.1%.
Strengths (1)
- Operating profit was 6.4 times interest costs.
- Shareholders' equity is small against the company's size, so return on equity and debt to equity are not shown.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally.
Read moreShow less
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
- Sector
- Healthcare
- Shares outstanding
- 193.8M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $52.6B
- P/E
- 33.8x
- P/B
- 34.9x
- EV / EBITDA
- 14.9x
- EV / Sales
- 0.2x
- P/S
- 0.2x
- 52-week high
- $374.75
- 52-week low
- $252.74
Profitability
- Operating margin
- 1.2%
- Net margin
- 0.5%
- EBITDA margin
- 1.2%
- ROE
- 103.1%
- ROCE
- 21.0%
- ROA
- 2.0%
- Asset turnover
- 4.20
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $321.3B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 9.3%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 10.4%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 3.0%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $3.2B
Solvency
- Current ratio
- 0.90
- Debt / Equity
- 5.08
- Debt / Assets
- 0.10
- CFO / Net profit
- 2.49
- Cash / Market cap
- 8.3%
Where the revenue went
Of every $100 of FY2025 revenue, $0 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $309.9B |
| Revenue | Gross profit | $11.5B |
| Gross profit | Selling, general and administrative | $6.5B |
| Gross profit | Other operating expenses | $1.1B |
| Gross profit | Operating income | $3.9B |
| Operating income | Pretax income | $2.3B |
| Operating income | Interest and other expense | $1.7B |
| Pretax income | Tax and other | $704.2M |
| Pretax income | Net income | $1.6B |
Revenue and net profit
Revenue grew 9.3% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $238.6B | $1.7B |
| FY2023 | $262.2B | $1.7B |
| FY2024 | $294.0B | $1.5B |
| FY2025 | $321.3B | $1.6B |
Cash flows
FY2025: $3.9B from operations, $3.2B free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $2.7B | $2.2B |
| FY2023 | $3.9B | $3.5B |
| FY2024 | $3.5B | $3.0B |
| FY2025 | $3.9B | $3.2B |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $321.3B+9.3%1Y
- EBITDA
- $3.7B+11.1%1Y
- Net profit
- $1.6B+3.0%1Y
- Cash from operations
- $3.9B+11.2%1Y
- Free cash flow
- $3.2B+7.0%1Y
- Revenue CAGR, 3Y
- 10.4%
- Net profit CAGR, 3Y
- -2.9%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $321.3B | $3.7B | $1.6B | $3.2B | 103.1% | +9.3% | +3.0% |
Monthly returns
Month-by-month returns of COR across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $76.6B |
| Current assets | $52.2B |
| Non-current assets | $24.4B |
| Liabilities | $74.8B |
| Current liabilities | $57.8B |
| Non-current liabilities | $17.0B |
| Equity | $1.7B |
| Paid-in capital | $6.2B |
| Retained earnings | $6.5B |
| Treasury stock | $10.3B |
| Minority interest | $239.1M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; COR highlighted.
P/E against peers
COR trades at 33.8x earnings against a peer median of 32.8x.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Cencora, Inc.CORthis company | $52.6B | 33.8x | 34.9x | 103.1% | 14.9x |
| Regeneron Pharmaceuticals, Inc.REGN | $65.9B | 14.6x | 2.1x | 14.4% | 11.3x |
| Edwards Lifesciences CorporationEW | $50.4B | 46.9x | 4.9x | 10.4% | 33.2x |
| Cardinal Health, Inc.CAH | $47.2B | 30.3x | -17.0x | -56.1% | 16.7x |
| IDEXX Laboratories, Inc.IDXX | $44.5B | 42.0x | 27.7x | 66.0% | 30.1x |
| Humana Inc.HUM | $42.0B | 35.4x | 2.4x | 6.7% | — |
| Becton, Dickinson and CompanyBDX | $41.2B | 24.6x | 1.6x | 6.6% | 12.1x |
| Alnylam Pharmaceuticals, Inc.ALNY | $40.5B | 129.2x | 51.4x | 39.8% | 61.6x |
| Agilent Technologies, Inc.A | $39.1B | 30.0x | 5.8x | 19.3% | 22.1x |
| Peer median | — | 32.8x | 3.6x | 12.4% | 22.1x |
Year-to-date ROI
COR since 1 January, against earlier years.
Historical volatility
COR's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 1.2% |
| FY2023 | 1.0% |
| FY2024 | 1.1% |
| FY2025 | 1.2% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $321.3B |
| Cost of revenueCost Of Revenue | $309.9B |
| Gross profitGross Profit | $11.5B |
| Operating expensesOperating Expense | $7.5B |
| Selling, general and administrativeSelling General And Administration | $6.5B |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $1.1B |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement | $1.1B |
| Depreciation income statementDepreciation Income Statement | $494.1M |
| Amortization | $556.9M |
| Amortisation of intangiblesAmortization Of Intangibles Income Statement | $556.9M |
| Total expensesTotal Expenses | $317.4B |
| Operating incomeOperating Income | $3.9B |
| Interest and other | |
| Pretax incomePretax Income | $2.3B |
| TaxTax Provision | $690.5M |
| Net incomeNet Income | $1.6B |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $76.6B |
| Current assetsCurrent Assets | $52.2B |
| Non-current assetsTotal Non Current Assets | $24.4B |
| LiabilitiesTotal Liabilities Net Minority Interest | $74.8B |
| Current liabilitiesCurrent Liabilities | $57.8B |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $17.0B |
| EquityTotal Equity Gross Minority Interest | $1.7B |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $3.9B |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $3.9B |
| Net income, continuing operationsNet Income From Continuing Operations | $1.6B |
| Depreciation and amortisationDepreciation And Amortization | $1.1B |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $1.1B |
| Depreciation | $501.3M |
| Amortization cash flowAmortization Cash Flow | $567.1M |
| Amortization of intangiblesAmortization Of Intangibles | $567.1M |
| Stock-based compensationStock Based Compensation | $148.0M |
| Deferred taxDeferred Tax | $59.9M |
| Deferred income taxDeferred Income Tax | $59.9M |
| Operating gains and lossesOperating Gains Losses | $130.3M |
| Gain loss on sale of businessGain Loss On Sale Of Business | $22.7M |
| Earnings losses from equity investmentsEarnings Losses From Equity Investments | $107.6M |
| Asset impairmentAsset Impairment Charge | $837.4M |
| Provision and write off of assetsProvisionand Write Offof Assets | $63.3M |
| Change in working capitalChange In Working Capital | $35.4M |
| Other non-cash itemsOther Non Cash Items | -$35.4M |
| Investing cash flowInvesting Cash Flow | -$5.0B |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$5.0B |
| Capital expenditureCapital Expenditure | -$668.0M |
| Capital expenditure (reported)Capital Expenditure Reported | -$668.0M |
| Sale of PP&ESale Of PPE | — |
| Net PP&E purchases and salesNet PPE Purchase And Sale | — |
| AcquisitionsPurchase Of Business | -$4.3B |
| DisposalsSale Of Business | — |
| Net acquisitions and disposalsNet Business Purchase And Sale | -$4.3B |
| Other investing changesNet Other Investing Changes | -$17.4M |
| Financing cash flowFinancing Cash Flow | $2.2B |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $2.2B |
| Debt issuedIssuance Of Debt | $136.6B |
| Debt repaidRepayment Of Debt | -$133.4B |
| Net debt issuedNet Issuance Payments Of Debt | $3.2B |
| Short-term debt issuedShort Term Debt Issuance | $132.1B |
| Short-term debt repaidShort Term Debt Payments | -$132.2B |
| Net short-term debt issuedNet Short Term Debt Issuance | -$32.2M |
| Long-term debt issuedLong Term Debt Issuance | $4.5B |
| Long-term debt repaidLong Term Debt Payments | -$1.3B |
| Net long-term debt issuedNet Long Term Debt Issuance | $3.2B |
| Shares issuedIssuance Of Capital Stock | — |
| Common stock issuedCommon Stock Issuance | — |
| Net common stock issuedNet Common Stock Issuance | -$435.5M |
| Common stock repurchasedCommon Stock Payments | -$435.5M |
| Share buybacksRepurchase Of Capital Stock | -$435.5M |
| Stock options exercisedProceeds From Stock Option Exercised | $29.1M |
| Dividends paidCash Dividends Paid | -$437.1M |
| Common dividends paidCommon Stock Dividend Paid | -$437.1M |
| Other financing chargesNet Other Financing Charges | -$103.1M |
| Change in cashChanges In Cash | $1.1B |
| Effect of exchange ratesEffect Of Exchange Rate Changes | -5,027.0% |
| Other cash adjustment outside change in cashOther Cash Adjustment Outside Changein Cash | — |
| Cash at the start of the yearBeginning Cash Position | $3.3B |
| Cash at the end of the yearEnd Cash Position | $4.4B |
| Free cash flowFree Cash Flow | $3.2B |
Learn while you research
Academy chapters picked for Cencora, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Valuation Multiples ExplainedThis stock trades at a P/E of 33.8, learn when high multiples are justified.6 min read
- 03 Leverage RatiosDebt/Equity of 5.08 is elevated, understand what that means for solvency.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read